TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
19.785
+0.255 (+1.31%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close19.530
Open19.628
Bid0.000 x 0
Ask0.000 x 0
Day's Range19.620 - 19.820
52 Week Range18.930 - 31.290
Volume275,029
Avg. Volume577,804
Market Cap31.127B
Beta (3Y Monthly)0.83
PE Ratio (TTM)28.49
EPS (TTM)0.695
Earnings DateN/A
Forward Dividend & Yield0.81 (4.07%)
Ex-Dividend Date2018-03-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist5 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Moody's6 days ago

    Seven & i Holdings Co., Ltd. -- Moody's: Rated Japanese corporates' cash to stay high, but pace of growth to slow

    Moody's Japan K.K. says that the cash levels of rated Japanese non-financial companies will remain high through at least fiscal 2018 -- ending 31 March 2019 for most companies -- but that the pace of growth will slow as spending increases. "One indication of this trend is the fact that cash as a percentage of assets, which peaked at more than 9% in fiscal 2015, has since declined and will continue to do so through fiscal 2018," says Mihoko Manabe, a Moody's Associate Managing Director. "Looking ahead, we also expect that the rated companies' cash holdings, which totaled JPY33.7 trillion (USD306 billion) at the end of fiscal 2017, will rise 2% in fiscal 2018 and hold steady in fiscal 2019, a slowdown from growth of 5% in fiscal 2017," says Manabe.

  • PR Newswire7 days ago

    New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's Disease

    DEERFIELD, Ill., Oct. 8, 2018 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., ("Takeda") today announced the presentation of new long-term efficacy real-world data analyses for Entyvio® (vedolizumab) at ACG 2018 in Philadelphia, PA. Studies of note include a retrospective multicentre cohort study of biologic-naïve adults with ulcerative colitis (UC) and Crohn's disease (CD), two systematic reviews and meta-analyses of real-world treatment persistence and mucosal healing, and a time-trend analysis of Entyvio utilization and outcomes across the United States (U.S.). A total of 10 Entyvio abstracts were accepted for presentation at the meeting.

  • Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline
    Reuters17 days ago

    Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

    EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc , the European Commission said on Friday. The EU ...

  • Reuters17 days ago

    Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline

    BRUSSELS (Reuters) - EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion (47.5 billion pounds) takeover of London-listed Shire Plc (SHP.L), ...

  • Japan Is Asia’s M&A King While China Gets the Pushback
    Bloomberg21 days ago

    Japan Is Asia’s M&A King While China Gets the Pushback

    Is it just China that faces roadblocks from the West when acquiring overseas assets, or are other foreign buyers equal targets? For the first time in three years, Japanese companies have pulled ahead of their mainland rivals, offering nearly double the $80 billion Chinese firms have shelled out for deals abroad so far this year. That makes Japan, not China, Asia’s M&A king. The Committee on Foreign Investment in the U.S. has hardened its stance toward foreign buying, no matter how small or passive, for companies that work in critical technology, infrastructure and the catch-all net of personal data — all with an eye to protecting U.S. national-security interests.

  • CNBC22 days ago

    Tell us what you think: Which sector will see the next mega-merger?

    The media space has seen a spate of major acquisition attempts in 2018, with the most recent being the long-running battle between Comcast and Twenty-First Century Fox for British broadcaster Sky. The pharmaceutical industry also saw a similar move earlier in the year, as Japan's Takeda Pharmaceutical reached an agreement for Shire. Over the weekend, Comcast CMCSA outbid Twenty-First Century Fox FOXA by $3.6 billion in a long-running battle between the two companies for British broadcaster, Sky.

  • Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says
    Bloomberg23 days ago

    Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says

    One of the top 10 shareholders in Japanese drugmaker Takeda Pharmaceutical Co. is “skeptical” on the value that will be created from the group’s $62 billion takeover of rare disease specialist Shire Plc, the Sunday Times reported, citing the unidentified investor. The deal, the biggest in Osaka-based Takeda’s history, has already faced opposition from a group of investors that calls itself “Thinking About Takeda’s Future.” It comprises former Takeda employees and shareholders who together own about 1 percent of the company’s stock and who oppose Takeda’s expansion. The Sunday Times reported the shareholder said the deal had come as a “surprise” and raised concerns about the ability of Takeda to cut costs and improve shareholder returns.

  • Reuters24 days ago

    Takeda lung cancer drug gets European panel nod

    Takeda Pharmaceutical Co's lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval to be sold in the United States. The European Medicines Agency's Committee for Medicinal Products for Human Use, recommended granting Japan-based Takeda's Alunbrig, or brigatinib, a marketing authorisation. The panel's recommendations are generally followed by European regulators.

  • Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
    Zacks25 days ago

    Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

    Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

  • Benzinga26 days ago

    Development Deal With Takeda Pharma Sends Molecular Templates Shares Rocketing Higher

    Molecular Templates Inc (NASDAQ: MTEM ) shares were advancing strongly Wednesday on significantly above-average volume, climbing to a four-month high. The stock was up nearly 62 percent at $6.64 at the ...

  • MarketWatch26 days ago

    Molecular Templates' stock soars after development deal with Takeda

    Shares of Molecular Templates Inc. soared 44% in premarket trade Wednesday, after the developer of cancer treatments announced a joint-development partnership with Japan-based Takeda Pharmaceutical Co. Ltd. . The companies will develop CD38-targeted toxin bodies for the treatment of multiple myeloma. Under terms of the agreement, Takeda will make an upfront payment of $30 million, and Molecular Templates will be eligible to receive up to $632.5 million in milestone payments if the company exercises its co-development option, or up to $337.5 in payments if the option is not exercised. The stock has tumbled 59% year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 10% and the S&P 500 has tacked on 8.6%.

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuterslast month

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuterslast month

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg
    Reuterslast month

    Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg

    Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks to cut the debt raised to fund the ...

  • Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg
    Reuterslast month

    Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg

    (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's (SHP.L) eye care business once it closes its $62 billion (47 billion pounds) purchase of the London-listed drugmaker, as it ...

  • Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected
    Reuterslast month

    Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

    The Deerfield site employs just under 1,000 people — about a fifth of its U.S. employees — and a number of them will be provided with job offers and/or relocation opportunities, a Takeda spokeswoman told Reuters on Wednesday. "This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. In May, Takeda agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion), a deal that will make the firm closer to becoming a top 10 global drugmaker.

  • Associated Presslast month

    Takeda moving US headquarters from Chicago area to Boston

    DEERFIELD, Ill. (AP) — Japanese drugmaker Takeda says it is closing its U.S. headquarters in suburban Chicago with about 1,000 employees and moving its functions to the Boston area.

  • Shire's ADHD Portfolio Remains Strong Amid Competition
    Zackslast month

    Shire's ADHD Portfolio Remains Strong Amid Competition

    Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

  • The Wall Street Journal2 months ago

    [$$] Third Rock, Takeda Launch Regenerative Medicine Startup for Liver Diseases

    Co. are launching Ambys Medicines with $140 million to develop regenerative medicines for liver diseases. Some 3.9 million U.S. adults have been diagnosed with liver disease, according to the Centers for Disease Control and Prevention. Ambys, formed by Third Rock and Takeda this year, is capitalizing on improved understanding of liver biology and advances in cell and gene therapy to treat liver conditions.

  • ACCESSWIRE2 months ago

    Takeda Pharmaceutical Co. Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Takeda Pharmaceutical Co. Ltd. (OTC PINK: TKPYY ) will be discussing their earnings results in their Q1 Earnings Call to be held on July 31, 2018 at 5:00 PM ...

  • Shire profit edges higher ahead of Takeda sale
    Reuters2 months ago

    Shire profit edges higher ahead of Takeda sale

    Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.